Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Halozyme Therapeutic
(NQ:
HALO
)
38.97
+0.26 (+0.67%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
557,948
Open
38.75
Bid (Size)
37.13 (2)
Ask (Size)
39.80 (150)
Prev. Close
38.71
Today's Range
38.70 - 39.42
52wk Range
29.85 - 45.00
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ:HALO is not too expensive for the growth it is showing.
Today 6:30 EDT
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
April 16, 2024
Via
Benzinga
Performance
YTD
+4.23%
+4.23%
1 Month
-3.59%
-3.59%
3 Month
+14.58%
+14.58%
6 Month
+12.08%
+12.08%
1 Year
+16.19%
+16.19%
More News
Read More
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
April 16, 2024
Via
Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
April 09, 2024
Via
Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
April 05, 2024
Via
Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
April 02, 2024
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
February 21, 2024
Via
Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
February 21, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
March 29, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
Via
Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
March 14, 2024
Via
Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
Via
InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
March 11, 2024
Via
Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
March 01, 2024
Via
Chartmill
Halozyme Therapeutics: Q4 Earnings Insights
February 20, 2024
Via
Benzinga
Earnings Preview: Halozyme Therapeutics
February 19, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
February 19, 2024
Via
Chartmill
Earnings Scheduled For February 20, 2024
February 20, 2024
Via
Benzinga
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
February 15, 2024
Via
Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
February 09, 2024
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
January 31, 2024
Via
Chartmill
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Via
Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
January 29, 2024
Via
Chartmill
NASDAQ:HALO: good value for what you're paying.
January 19, 2024
Via
Chartmill
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.